4DMedical advancing to commercial execution
Recent announcements highlight early adoption by leading US hospitals strengthening clinical validation and providing insight into the company’s strategy to scale revenue and build long term value.
4DMedical Limited (ASX: 4DX)
is transitioning from regulatory success to commercial execution and recent developments indicate that the company is laying a strong foundation for long-term growth.
On 30 January 2026 announced that University of Chicago Medicine adopted CT: VQ™ for commercial use becoming the fifth leading US academic medical centre to deploy the technology within just five months of FDA clearance.
This follows earlier adoption by Stanford, Cleveland Clinic, UC San Diego Health and the University of Miami.
This pattern of adoption is strategically important. Academic medical centres act as the key opinion leaders in the healthcare. Their clinical endorsement helps to validate new technologies, strengthens reimbursement confidence and accelerates downstream adoption across broader hospital networks.
While early scan volumes may be modest, these institutions often evolve into long term, high-value customers as clinical workflows mature.
CT: VQ™ delivers ventilation perfusion insights from a standard non-contrast CT scan eliminating the need for nuclear imaging infrastructure.
This significantly reduces adoption friction and expands the addressable market particularly across community and regional hospitals that may lack access to traditional nuclear medicine facilities.
To support this momentum the company completed a $150 million institutional placement at $3.80 per share limiting dilution to just 3.86%.
The company holds a pro-forma cash balance exceeding $200 million providing substantial financial flexibility to scale sales, marketing and customer success initiatives in the US. Management confidence was further reinforced by the CEO and CFO increasing their shareholdings as part of the transaction.
The Q2 FY26 update highlights improving operational traction. Underlying SaaS revenue grew 31% in H1 FY26 scan volumes more than doubled year on year and CT: VQ™ received Health Canada approval unlocking a new growth market.
The expanded Philips distribution partnership which includes minimum order commitments adds further visibility to the commercial rollout.
(Source: Company Announcements)
Get Your Free Report on Top 5 ASX Stocks on WhatsApp
Instant Access. No Credit Card Required.
Receive on WhatsApp
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialASX Stock Research & Recommendations — 7‑day free trial
Independent, analyst‑driven insights.
- Stock of the week report
- Daily Analysis Report
- No credit card required
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Article
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
